{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:41:46Z","timestamp":1790743306384,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2014,12,17]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Premature cardiovascular disease limits the duration and quality of life on long\u2010term hemodialysis. The objective of this study was to define the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerotic mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during the EValuation of Cinacalcet\n                      <jats:styled-content style=\"fixed-case\">HC<\/jats:styled-content>\n                      l Therapy to Lower CardioVascular Events (\n                      <jats:styled-content style=\"fixed-case\">EVOLVE<\/jats:styled-content>\n                      ) Trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      <jats:styled-content style=\"fixed-case\">EVOLVE<\/jats:styled-content>\n                      was a randomized, double\u2010blind, placebo\u2010controlled clinical trial that randomized 3883 hemodialysis patients with moderate to severe secondary hyperparathyroidism to cinacalcet or matched placebo for up to 64\u00a0months. For this post hoc analysis, the outcome measure was fatal and nonfatal cardiovascular events reflecting atherosclerotic and nonatherosclerotic cardiovascular diseases. During the trial, 1518 patients experienced an adjudicated cardiovascular event, including 958 attributable to nonatherosclerotic disease. Of 1421 deaths during the trial, 768 (54%) were due to cardiovascular disease. Sudden death was the most frequent fatal cardiovascular event, accounting for 24.5% of overall mortality. Combining fatal and nonfatal cardiovascular events, randomization to cinacalcet reduced the rates of sudden death and heart failure. Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative hazard 0.84, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Accepting the limitations of post hoc analysis, any benefits of cinacalcet on cardiovascular disease in the context of hemodialysis may result from attenuation of nonatherosclerotic processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Unique identifier: NCT00345839. URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.114.001363","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T23:46:09Z","timestamp":1416267969000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":122,"title":["Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial"],"prefix":"10.1161","volume":"3","author":[{"given":"David C.","family":"Wheeler","sequence":"first","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"London","sequence":"additional","affiliation":[{"name":"H\u00f4pital Manh\u00e8s, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[{"name":"Health Sciences Center St. John's, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[{"name":"Denver Nephrology, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa\u2010Rotter","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Dr\u00fceke","sequence":"additional","affiliation":[{"name":"Inserm Unit 1088, UFR M\u00e9decine\/Pharmacie, Universit\u00e9 de Picardie, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum der RWTH Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Moe","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Louise","family":"Trotman","sequence":"additional","affiliation":[{"name":"Amgen, Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Abdalla","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Herzog","sequence":"additional","affiliation":[{"name":"Hennepin County Medical Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","volume-title":"USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End\u2010Stage Renal Disease in the United States","author":"U.S. Renal Data System","year":"2012","unstructured":"U.S. Renal Data System . USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End\u2010Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00657.x"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043545"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.037"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-6193-9.10055-7"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810177"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04381206"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr777"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1989.10478873"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/68.2.373"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-4-201208210-00005"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-88"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.020"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.234914"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122"},{"key":"e_1_3_5_22_2","first-page":"S116","article-title":"Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension","volume":"9","author":"Duprez D","year":"1991","unstructured":"Duprez D, Bauwens F, De Buyzere M, De Backer T, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL. Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension. J Hypertens Suppl. 1991;9:S116\u2013S117.","journal-title":"J Hypertens Suppl"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184887"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90602-9"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq725"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm660"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr384"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.03.026"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0085-2538(15)50904-6"}],"updated-by":[{"DOI":"10.1161\/jaha.114.000570","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000}}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.114.001363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:39:04Z","timestamp":1715582344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.114.001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12,17]]}},"alternative-id":["10.1161\/JAHA.114.001363"],"URL":"https:\/\/doi.org\/10.1161\/jaha.114.001363","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]},"assertion":[{"value":"2014-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e001363"}}